Purified anti-mouse IL-10 Antibody
- 产品名称：
- Purified anti-mouse IL-10 Antibody
- 产品类别：
- 抗体
- 产品编号：
- 505001
- 产品应用：
- 505001
- Verified Reactivity
- Mouse
- Antibody Type
- Monoclonal
- Host Species
- Rat
- Immunogen
- E. coli-expressed, recombinant mouse IL-10
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
- Preparation
- The antibody was purified by affinity chromatography.
- Concentration
- 0.5 mg/ml
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C.
- Application
-
ELISA Capture - Quality tested
CyTOF? - Verified
IHC - Reported in the literature, not verified in house
- Recommended Usage
Each lot of this antibody is quality control tested by ELISA assay. For ELISA capture applications, a concentration range of 0.1 - 1.0 ?g/ml is recommended. It is recommended that the reagent be titrated for optimal performance for each application. To obtain a linear standard curve, serial dilutions of IL-10 recombinant protein ranging from 2000 to 15 pg/ml are recommended for each ELISA plate. For ELISA capture, Carbonate buffer, pH 9.5 is highly recommended for coating buffer.
- Application Notes
ELISA or ELISPOT Detection1,9,11: The biotinylated JES5-16E3 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified JES5-2A5 antibody (Cat. Nos. 504902 & 504904) as the capture antibody.
ELISA Capture: The purified JES5-16E3 antibody is useful as the capture antibody in a sandwich ELISA when used in conjunction with the biotinylated JES5-2A5 antibody (Cat. No. 505003) as the detection antibody and recombinant mouse IL-10 (Cat. No. 575809) as the standard.
Neutralization14: The Ultra-LEAF? purified JES5-16E3 antibody can neutralize the bioactivity of natural or recombinant IL-10.
Flow Cytometry3: The fluorochrome-labeled JES5-16E3 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IL-10-producing cells within mixed cell populations.
Additional reported applications (for relevant formats) include: immunohistochemistry3.
- Application References
(PubMed link indicates BioLegend citation) -
- Simkin G, et al. 2000. J. Immunol. 164:2457.
- Kitagaki K, et al. 2002. Clin. Diagn. Lab Immunol. 9:1260.
- Khanna A, et al. 2000. J. Immunol. 164:1346.
- Sander B, et al. 1993. J. Immunol. Methods 166:201.
- Litton M, et al. 1994. J. Immunol. Methods 175:47.
- Andersson U, et al. 1999. Detection and qunatification of gene expression. New York:Springer-Verlag.
- Finkelman F, et al. 2003. Curr. Prot. Immunol. John Wiley & Sons New York. Unit 6.28.
- Wang W, et al. 2004. FASEB J. 18:1043.
- Brummel R and Lenert P. 2005. J. Immunol. 174:2429.
- Lawson BR, et al. 2007. J. Immunol. 178:5366.
- Xu G, et al. 2007. J. Immunol. 179:5358. PubMed
- Brummel R, et al. 2005. J. Immunol.174:2429. PubMed
- Kang YJ, et al. 2007. Stem Cells 25:1814. PubMed
- Seo N, et al. 2001. Immunology. 103:449. (Neut)
- Product Citations
-
- Smith CJ, et al. 2018. J Immunol. 200:1580. PubMed
- Burrello C, et al. 2018. Front Med (Lausanne). 5:21. PubMed
- Wang W, et al. 2018. Cancer Cell. 34:757. PubMed
- Volpedo G, et al. 2022. NPJ Vaccines. 7:32. PubMed
- Draganov D, et al. 2021. NPJ Breast Cancer. 7:22. PubMed
- Mencarelli A, et al. 2018. Front Immunol. 9:261. PubMed
- Kang Y, et al. 2007. Stem Cells. 25:1814. PubMed
- Bittner-Eddy PD, et al. 2020. Front Immunol. 11:677. PubMed
- Felton JL, et al. 2018. J Immunol. 201:861. PubMed
- Sun Y, et al. 2020. J Immunol. 205:3358. PubMed
- Daley D, et al. 2017. Nat Med. 23:556. PubMed
- Muhammad F, et al. 2020. J Autoimmun. 111:102441. PubMed
- González LA, et al. 2021. Front Immunol. 12:638917. PubMed
- Ranjan K, et al. 2021. J Clin Invest. 131:. PubMed
- Lenert R 2005. J Immunol. 174:2429. PubMed
- Scortegagna M, et al. 2020. Nat Commun. 11:99. PubMed
- Xu G, et al. 2007. J Immunol. 179:5358. PubMed
- Huang TX, et al. 2022. Gut. 71:333. PubMed
- Field CS, et al. 2020. Cell Metab. 31:422. PubMed
- Pushalkar S, et al. 2018. Cancer Discov. 0.613194444. PubMed
- Umeda M, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
- RRID
- AB_315355 (BioLegend Cat. No. 505001) AB_315356 (BioLegend Cat. No. 505002)
- Structure
- Acid-labile cytokine, dimer, 17-21 kD (Mammalian)
- Cell Sources
- Activated CD8+ T cells, Th0, Th2 subset of CD4+ T cells, Ly-1+ B cells, monocytes, macrophages, keratinocytes
- Cell Targets
- T cells, B cells, mast cells, macrophages
- Receptors
- IL-10R (CDw210)
- Cell Type
- Tregs
- Biology Area
- Immunology
- Molecular Family
- Cytokines/Chemokines
- Antigen References
-
1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. de Waal-Malefy R, et al. 1992. Curr. Opin. Immunol. 4:314.
3. Howard M, et al. 1992. Immunol. Today 13:198.
4. Quesniaux V. 1992. Res. Immunol. 143:385.
5. Norton SK, et al. 2008. J. Immunol. 180:2848.
- Regulation
- Downregulated by IL-4, IL-10
- Gene ID
- 16153 View all products for this Gene ID
- UniProt
- View information about IL-10 on UniProt.org
